▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #874 by analyst upside · 2026-11-13
RAPP
Rapport Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+148.4%
implied upside to consensus target
Current Price $25.85
Consensus Target $64.21
Bull Target $89.0
Bear Target $47.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
13
Hold
0
Sell
0
52-Week Low $22.06
52-Week High $52.93
YTD Return -8.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $20M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $22.06
52-Week High $52.93
Current Price $25.85
Bear Target $47.0
Bull Target $89.0
● Now $25.85 ● Target $64.21
TRADING DATA
Avg Volume 762K
YTD Return -8.0%
Analyst Count 14
Consensus Buy
Upside to Target +148.4%
Last Updated 2026-11-13

ANALYST SUMMARY

Rapport Therapeutics, Inc. (RAPP) is currently trading at $25.85 with a Wall Street consensus price target of $64.21, implying potential upside of 148.4% over the next 12 months. 14 analysts currently cover RAPP, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $89.0, while the most cautious has a target of $47.0.

RAPP operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 8.0% year-to-date and is currently trading near the lower end of its 52-week range of $22.06 – $52.93.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RAPP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-11-06 33% win rate (6 calls)
Guggenheim - Reiterated
Buy → Buy 2026-11-05 62% win rate (8 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-11-05 Building track record
Jones Trading - Reiterated
Buy → Buy 2026-10-21 57% win rate (14 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-10-21 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-10-21 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-10-20 31% win rate (48 calls)
BTIG - Reiterated
Buy → Buy 2026-10-20 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →